KCNJ10 and myeloid sarcoma: Another recent study failed to detect enriched KIR4.1 autoantibodies in Japanese patents with MS (57 patients) or NMO (40 patients including NMO spectrum disorders), compared to 50 healthy controls (all were Japanese; Higuchi et al., 2016).